Read More

Initial Phase 1 Dose Escalation Data For ORIC-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development At The 65th American Society Of Hematology Annual Meetin…

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose

ORIC

Read More

Results From SURMOUNT-4 Published In JAMA Showed Zepbound Met The Primary Endpoint Of Mean Percent Change In Body Weight, And All Key Secondary Endpoints For Both Estimands, Compared To Placebo 52 Weeks After Randomization

People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placeboFull results from the SURMOUNT-4

LLY